{
    "relation": [
        [
            "",
            "EFV, FTC/TDF, and Placebo ABC/3TC",
            "EFV, Placebo FTC/TDF, and ABC/3TC",
            "RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC",
            "RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC"
        ],
        [
            "Description",
            "Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks",
            "Participants will receive EFV, placebo for FTC/TDF, and ABC/3TC for at least 96 weeks",
            "Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks",
            "Participants will receive RTV-boosted ATV, placebo for FTC/TDF, and ABC/3TC for at least 96 weeks"
        ]
    ],
    "pageTitle": "Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00118898?sect=Xk015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987135.9/warc/CC-MAIN-20150728002307-00116-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 877751491,
    "recordOffset": 877733013,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 1864 were randomized. Results reported for 1857 eligible participants; 7 were subsequently found ineligible and excluded from all analyses. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Recruited at AIDS Clinical Trials Units in the United States and Puerto Rico. Recruitment occurred between September 21, 2005 (date first subject was randomized) and November 20, 2007 (date last subject was randomized). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Abacavir/Lamivudine Drug: Atazanavir Drug: Efavirenz Drug: Emtricitabine/Tenofovir disoproxil fumarate Drug: Ritonavir Drug: Abacavir/Lamivudine placebo Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo Interventions: HIV Infections",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 EFV, FTC/TDF, and Placebo ABC/3TC \u00a0 \u00a0 EFV, Placebo FTC/TDF, and ABC/3TC \u00a0 \u00a0 RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC \u00a0 \u00a0 RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC \u00a0 STARTED \u00a0 \u00a0 464 \u00a0 \u00a0 465 \u00a0 \u00a0 465 \u00a0 \u00a0 463 \u00a0 Initiated Treatment \u00a0 \u00a0 461 \u00a0 \u00a0 461 \u00a0 \u00a0 464 \u00a0 \u00a0 462 \u00a0 COMPLETED \u00a0 \u00a0 343 \u00a0 \u00a0 324 \u00a0 \u00a0 342 \u00a0 \u00a0 322 \u00a0 NOT COMPLETED \u00a0 \u00a0 121 \u00a0 \u00a0 141 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}